microRNA Replacement Therapy
Investor Relations

Mirna is a biopharmaceutical company focused on the development of microRNA-based oncology therapeutics. Mirna’s first product candidate, MRX34, the first microRNA mimic to enter clinical development in oncology, was studied as a single agent in a multicenter Phase 1 clinical trial, which included patients with primary liver cancer, other solid cancers, and hematological malignancies. In September 2016, Mirna voluntarily halted enrollment and dosing in the clinical study following multiple immune-related serious adverse events (SAEs) observed in patients dosed with MRX34 over the course of the trial. The Company is currently evaluating opportunities to enhance stockholder value.

© 2017 Mirna Therapeutics, Inc. All Rights Reserved.